Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

Oral hexadecyloxypropyl-cidofovir therapy in pregnant guinea pigs improves outcome in the congenital model of cytomegalovirus infection.

Bravo FJ, Bernstein DI, Beadle JR, Hostetler KY, Cardin RD.

Antimicrob Agents Chemother. 2011 Jan;55(1):35-41. doi: 10.1128/AAC.00971-10. Epub 2010 Nov 15.

2.

Effect of maternal treatment with cyclic HPMPC in the guinea pig model of congenital cytomegalovirus infection.

Bravo FJ, Cardin RD, Bernstein DI.

J Infect Dis. 2006 Feb 15;193(4):591-7. Epub 2006 Jan 13.

PMID:
16425139
3.

Oral activity of ether lipid ester prodrugs of cidofovir against experimental human cytomegalovirus infection.

Bidanset DJ, Beadle JR, Wan WB, Hostetler KY, Kern ER.

J Infect Dis. 2004 Aug 1;190(3):499-503. Epub 2004 Jul 1.

PMID:
15243923
4.

Oral treatment of murine cytomegalovirus infections with ether lipid esters of cidofovir.

Kern ER, Collins DJ, Wan WB, Beadle JR, Hostetler KY, Quenelle DC.

Antimicrob Agents Chemother. 2004 Sep;48(9):3516-22.

5.
6.

Safety of cidofovir by intratympanic delivery technique.

Ward JA, Sidell DR, Nassar M, Reece AL, Choo DI.

Antivir Ther. 2014;19(1):97-105. doi: 10.3851/IMP2693. Epub 2013 Oct 24.

PMID:
24153022
7.

Effect of oral treatment with (S)-HPMPA, HDP-(S)-HPMPA or ODE-(S)-HPMPA on replication of murine cytomegalovirus (MCMV) or human cytomegalovirus (HCMV) in animal models.

Quenelle DC, Collins DJ, Pettway LR, Hartline CB, Beadle JR, Wan WB, Hostetler KY, Kern ER.

Antiviral Res. 2008 Aug;79(2):133-5. doi: 10.1016/j.antiviral.2008.01.155. Epub 2008 Feb 22.

8.

Micelle formulation of hexadecyloxypropyl-cidofovir (HDP-CDV) as an intravitreal long-lasting delivery system.

Ma F, Nan K, Lee S, Beadle JR, Hou H, Freeman WR, Hostetler KY, Cheng L.

Eur J Pharm Biopharm. 2015 Jan;89:271-9. doi: 10.1016/j.ejpb.2014.12.010. Epub 2014 Dec 13.

9.

Replication-defective lymphocytic choriomeningitis virus vectors expressing guinea pig cytomegalovirus gB and pp65 homologs are protective against congenital guinea pig cytomegalovirus infection.

Cardin RD, Bravo FJ, Pullum DA, Orlinger K, Watson EM, Aspoeck A, Fuhrmann G, Guirakhoo F, Monath T, Bernstein DI.

Vaccine. 2016 Apr 12;34(17):1993-9. doi: 10.1016/j.vaccine.2016.03.005. Epub 2016 Mar 10.

PMID:
26973071
10.

Effects of four antiviral substances on lethal vaccinia virus (IHD strain) respiratory infections in mice.

Smee DF, Wong MH, Bailey KW, Beadle JR, Hostetler KY, Sidwell RW.

Int J Antimicrob Agents. 2004 May;23(5):430-7.

PMID:
15120719
11.

Oral treatment of cowpox and vaccinia virus infections in mice with ether lipid esters of cidofovir.

Quenelle DC, Collins DJ, Wan WB, Beadle JR, Hostetler KY, Kern ER.

Antimicrob Agents Chemother. 2004 Feb;48(2):404-12. Erratum in: Antimicrob Agents Chemother. 2004 May;48(5):1919.

12.
13.

Intraocular safety and pharmacokinetics of hexadecyloxypropyl-cidofovir (HDP-CDV) as a long-lasting intravitreal antiviral drug.

Wang H, Chhablani J, Freeman WR, Beadle JR, Hostetler KY, Hartmann K, Conner L, Aldern KA, Pearson L, Cheng L.

Invest Ophthalmol Vis Sci. 2011 Dec 9;52(13):9391-6. doi: 10.1167/iovs.11-8293.

14.
15.

Synthesis, metabolic stability and antiviral evaluation of various alkoxyalkyl esters of cidofovir and 9-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]adenine.

Ruiz J, Beadle JR, Buller RM, Schreiwer J, Prichard MN, Keith KA, Lewis KC, Hostetler KY.

Bioorg Med Chem. 2011 May 1;19(9):2950-8. doi: 10.1016/j.bmc.2011.03.034. Epub 2011 Mar 23.

16.

Predictive efficacy of SCID-hu mouse models for treatment of human cytomegalovirus infections.

Kern ER, Rybak RJ, Hartline CB, Bidanset DJ.

Antivir Chem Chemother. 2001;12 Suppl 1:149-56.

PMID:
11594682
17.

Cidofovir as primary pre-emptive therapy for post-transplant cytomegalovirus infections.

Chakrabarti S, Collingham KE, Osman H, Fegan CD, Milligan DW.

Bone Marrow Transplant. 2001 Nov;28(9):879-81.

18.

Intraocular properties of hexadecyloxypropyl-cyclic-cidofovir in Guinea pigs.

Lu S, Cheng L, Hostetler KY, Koh HJ, Beadle JR, Davidson MC, Freeman WR.

J Ocul Pharmacol Ther. 2005 Jun;21(3):205-9.

PMID:
15969637
19.

Efficacy of oral active ether lipid analogs of cidofovir in a lethal mousepox model.

Buller RM, Owens G, Schriewer J, Melman L, Beadle JR, Hostetler KY.

Virology. 2004 Jan 20;318(2):474-81.

20.

Alkoxyalkyl esters of cidofovir and cyclic cidofovir exhibit multiple-log enhancement of antiviral activity against cytomegalovirus and herpesvirus replication in vitro.

Beadle JR, Hartline C, Aldern KA, Rodriguez N, Harden E, Kern ER, Hostetler KY.

Antimicrob Agents Chemother. 2002 Aug;46(8):2381-6.

Supplemental Content

Support Center